{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:03:04Z","timestamp":1784822584456,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00941-z","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:39:23Z","timestamp":1778081963000},"page":"1691-1701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive Factors for Non-response to First Use of Polyvalent Intravenous Immunoglobulin in Generalised Myasthenia Gravis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1966-1295","authenticated-orcid":false,"given":"Matthias","family":"Dion","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Gavoille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Chamouard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pegat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Bouhour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"26","key":"941_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375(26):2570\u201381. https:\/\/doi.org\/10.1056\/NEJMra1602678.","journal-title":"N Engl J Med"},{"key":"941_CR2","unstructured":"Centre de r\u00e9f\u00e9rences de pathologie neuromusculaire Paris Est. Protocole National de Diagnostic et de Soins (PNDS) myasth\u00e9nie autoimmune. 2015. Accessed 5 Jan 2026. https:\/\/www.hassante.fr\/upload\/docs\/application\/pdf\/2015-07\/pnds_-_myasthenie_autoimmune.pdf"},{"issue":"5","key":"941_CR3","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/wnl.48.5.1253","volume":"48","author":"CE Thomas","year":"1997","unstructured":"Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology. 1997;48(5):1253\u201360. https:\/\/doi.org\/10.1212\/wnl.48.5.1253.","journal-title":"Neurology"},{"issue":"1","key":"941_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.27832","volume":"68","author":"B Claytor","year":"2023","unstructured":"Claytor B, Cho SM, Li Y. Myasthenic crisis. Muscle Nerve. 2023;68(1):8\u201319. https:\/\/doi.org\/10.1002\/mus.27832.","journal-title":"Muscle Nerve"},{"issue":"6","key":"941_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061597","volume":"11","author":"MK Alhaidar","year":"2022","unstructured":"Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current treatment of myasthenia gravis. J Clin Med. 2022;11(6):1597. https:\/\/doi.org\/10.3390\/jcm11061597.","journal-title":"J Clin Med"},{"issue":"6","key":"941_CR6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.410410615","volume":"41","author":"P Gajdos","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997;41(6):789\u201396. https:\/\/doi.org\/10.1002\/ana.410410615.","journal-title":"Ann Neurol"},{"issue":"16 Suppl 3","key":"941_CR7","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.2146\/ajhp050283","volume":"62","author":"M Ballow","year":"2005","unstructured":"Ballow M. Clinical and investigational considerations for the use of IGIV therapy. Am J Health Syst Pharm. 2005;62(16 Suppl 3):S12\u201318. https:\/\/doi.org\/10.2146\/ajhp050283.","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"941_CR8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.intimp.2005.11.013","volume":"6","author":"J Bayry","year":"2006","unstructured":"Bayry J, Dasgupta S, Misra N, et al. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int Immunopharmacol. 2006;6(4):528\u201334. https:\/\/doi.org\/10.1016\/j.intimp.2005.11.013.","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"941_CR9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1001\/archneur.1993.00540080046012","volume":"50","author":"RB Stricker","year":"1993","unstructured":"Stricker RB, Kwiatkowska BJ, Habis JA, Kiprov DD. Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin. Arch Neurol. 1993;50(8):837\u201340. https:\/\/doi.org\/10.1001\/archneur.1993.00540080046012.","journal-title":"Arch Neurol"},{"issue":"6","key":"941_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00730","volume":"22","author":"R Guo","year":"2025","unstructured":"Guo R, Sun C, Huang X, et al. Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: a retrospective cohort study. Neurotherapeutics. 2025;22(6):e00730. https:\/\/doi.org\/10.1016\/j.neurot.2025.e00730.","journal-title":"Neurotherapeutics"},{"issue":"7","key":"941_CR11","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1007\/s10072-025-08128-4","volume":"46","author":"C Messina","year":"2025","unstructured":"Messina C, Basile L, Crescimanno G, et al. Prominent and fast response to Eculizumab in myasthenic crisis: the potential as rescue therapy in refractory myasthenia gravis. Neurol Sci. 2025;46(7):3299\u2013302. https:\/\/doi.org\/10.1007\/s10072-025-08128-4.","journal-title":"Neurol Sci"},{"key":"941_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2025.109011","volume":"256","author":"E Rossini","year":"2025","unstructured":"Rossini E, Morino S, Garibaldi M, et al. Emergent role of complement inhibitors in myasthenic crisis: understanding why, when and how. Clin Neurol Neurosurg. 2025;256:109011. https:\/\/doi.org\/10.1016\/j.clineuro.2025.109011.","journal-title":"Clin Neurol Neurosurg"},{"issue":"23","key":"941_CR13","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017\u201323. https:\/\/doi.org\/10.1212\/WNL.0b013e31821e5505.","journal-title":"Neurology"},{"issue":"5","key":"941_CR14","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/mus.23236","volume":"45","author":"HD Katzberg","year":"2012","unstructured":"Katzberg HD, Barnett C, Bril V. Predictors of response to immunomodulation in patients with myasthenia gravis. Muscle Nerve. 2012;45(5):648\u201352. https:\/\/doi.org\/10.1002\/mus.23236.","journal-title":"Muscle Nerve"},{"issue":"2","key":"941_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/mus.20908","volume":"37","author":"L Zinman","year":"2008","unstructured":"Zinman L, Baryshnik D, Bril V. Surrogate therapeutic outcome measures in patients with myasthenia gravis. Muscle Nerve. 2008;37(2):172\u20136. https:\/\/doi.org\/10.1002\/mus.20908.","journal-title":"Muscle Nerve"},{"issue":"11","key":"941_CR16","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","volume":"68","author":"L Zinman","year":"2007","unstructured":"Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68(11):837\u201341. https:\/\/doi.org\/10.1212\/01.wnl.0000256698.69121.45.","journal-title":"Neurology"},{"issue":"3","key":"941_CR17","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/mus.21533","volume":"41","author":"M Pasnoor","year":"2010","unstructured":"Pasnoor M, Wolfe GI, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve. 2010;41(3):370\u20134. https:\/\/doi.org\/10.1002\/mus.21533.","journal-title":"Muscle Nerve"},{"issue":"1","key":"941_CR18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","volume":"44","author":"JT Guptill","year":"2011","unstructured":"Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36\u201340. https:\/\/doi.org\/10.1002\/mus.22006.","journal-title":"Muscle Nerve"},{"issue":"4","key":"941_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419\u201325. https:\/\/doi.org\/10.1212\/WNL.0000000000002790.","journal-title":"Neurology"},{"key":"941_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A, et al. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 2023;16:17562864231213240. https:\/\/doi.org\/10.1177\/17562864231213240.","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"941_CR21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s004150050585","volume":"247","author":"T Sharshar","year":"2000","unstructured":"Sharshar T, Chevret S, Mazighi M, et al. Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. J Neurol. 2000;247(4):286\u201390. https:\/\/doi.org\/10.1007\/s004150050585.","journal-title":"J Neurol"},{"issue":"10","key":"941_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint17100163","volume":"17","author":"S Takahashi","year":"2025","unstructured":"Takahashi S, Kinno R. Management of myasthenic crisis and emerging roles of molecularly targeted therapies: a narrative review. Neurol Int. 2025;17(10):163. https:\/\/doi.org\/10.3390\/neurolint17100163.","journal-title":"Neurol Int"},{"issue":"7","key":"941_CR23","doi-asserted-by":"publisher","first-page":"8287","DOI":"10.1007\/s00210-025-03954-x","volume":"398","author":"P Tang","year":"2025","unstructured":"Tang P, He Y, Xiao K, Wang L. A systematic review of efgartigimod as an effective treatment for myasthenic crisis. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(7):8287\u201394. https:\/\/doi.org\/10.1007\/s00210-025-03954-x.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"941_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;10:46. https:\/\/doi.org\/10.1186\/1471-2377-10-46.","journal-title":"BMC Neurol"},{"issue":"1","key":"941_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s13760-016-0689-z","volume":"117","author":"A Alipour-Faz","year":"2017","unstructured":"Alipour-Faz A, Shojaei M, Peyvandi H, et al. A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients. Acta Neurol Belg. 2017;117(1):245\u20139. https:\/\/doi.org\/10.1007\/s13760-016-0689-z.","journal-title":"Acta Neurol Belg"},{"issue":"8","key":"941_CR26","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German Neurological Society. J Neurol. 2016;263(8):1473\u201394. https:\/\/doi.org\/10.1007\/s00415-016-8045-z.","journal-title":"J Neurol"},{"issue":"1","key":"941_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30154-5","volume":"13","author":"M Tomschik","year":"2023","unstructured":"Tomschik M, Renaud E, J\u00e4ger F, et al. The diagnostic and prognostic utility of repetitive nerve stimulation in patients with myasthenia gravis. Sci Rep. 2023;13(1):2985. https:\/\/doi.org\/10.1038\/s41598-023-30154-5.","journal-title":"Sci Rep"},{"key":"941_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jocn.2024.01.025","volume":"121","author":"A Ghimire","year":"2024","unstructured":"Ghimire A, Kunwar B, Aryal B, et al. Assessing the comparative efficacy of plasmapheresis and intravenous immunoglobulin in myasthenia gravis treatment: a systematic review and meta-analysis. J Clin Neurosci. 2024;121:1\u201310. https:\/\/doi.org\/10.1016\/j.jocn.2024.01.025.","journal-title":"J Clin Neurosci"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00941-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00941-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00941-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:26Z","timestamp":1784819486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00941-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["941"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00941-z","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Antoine Pegat has received consultancy fees, congress travel support and meeting participation fees from CSL Behring. Francoise Bouhour has received consultancy fees, congress travel support and meeting participation fees from CSL Behring. Val\u00e9rie Chamouard has received consultancy fees, congress travel support and meeting participation fees from Novo Nordisk and Roche. Matthias Dion and Antoine Gavoille declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and applicable national regulations on data protection. The study protocol was reviewed by the institutional ethics committee (Comit\u00e9 d\u2019\u00e9thique, HCL number 23-5460), which issued a favorable opinion. Patients were informed about the use of their anonymised data and did not express any opposition to its use for research purposes.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}